Latest Articles
Circular RNAs as a novel class of potential therapeutic and diagnostic biomarkers in reproductive biology/diseases.
Infertility is a prevalent problem among 10% of people within their reproductive years. Sometimes, even advanced treatment options like assisted reproduction technology have the potential to result in failed implantation. …
Published: Dec. 31, 2024, midnight
Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers - www.oncnursingnews.com/
Lunresertib/Camonsertib Combo Yields Promising Response in Gynecologic Cancers www.oncnursingnews.com/
Published: Dec. 26, 2024, 7:07 p.m.
Top Gynecologic Cancer Research of 2024 - Cancer Therapy Advisor
Top Gynecologic Cancer Research of 2024 Cancer Therapy Advisor
Published: Dec. 9, 2024, 3 p.m.
Balancing VTE and bleeding risks in gynecologic cancer surgeries - Contemporary Obgyn
Balancing VTE and bleeding risks in gynecologic cancer surgeries Contemporary Obgyn
Published: Dec. 6, 2024, 8:37 p.m.
Butyrate as a Potential Modulator in Gynecological Disease Progression.
This review investigates the therapeutic potential of butyrate, a short-chain fatty acid (SCFA) produced by gut microbiota, in the prevention and treatment of various gynecological diseases, including polycystic ovary syndrome …
Published: Dec. 4, 2024, midnight
Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers - Physician's Weekly
Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers Physician's Weekly
Published: Nov. 30, 2024, 10:44 a.m.
Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers - 2 Minute Medicine
Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers 2 Minute Medicine
Published: Nov. 30, 2024, 12:15 a.m.
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens - OncLive
Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens OncLive
Published: Nov. 5, 2024, 3:07 p.m.
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers - BioSpace
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers BioSpace
Published: Oct. 24, 2024, 11:46 a.m.
Approval From European Commission With Two New Indications in Gynecologic Cancers - businesswire.com
Approval From European Commission With Two New Indications in Gynecologic Cancers businesswire.com
Published: Oct. 24, 2024, 10:45 a.m.
Link copied to clipboard!